Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism. However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment. Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice. Moreover, tumour EZH2 and DNMT1 are negatively associated with tumour-infiltrating CD8(+) T cells and patient outcome. Thus, epigenetic silencing of TH1-type chemokines is a novel immune-evasion mechanism of tumours. Selective epigenetic reprogramming alters the T-cell landscape in cancer and may enhance the clinical efficacy of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epigenetic reprogramming with shRNAs targeting DNA methyltransferase 1 (DNMT1) or pan-DNMT blockers like decitabine and guadecitabine has been shown to resemble EZH2 inhibition in its capacity to promote CXCL9 and CXCL10 secretion in various models of breast, lung, and ovarian carcinoma”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The mTOR pathway has long been recognized to play a pivotal role in integrating signals at the cellular level and promote autoimmunity and carcinogenesis18,19.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“and TH1 cytokines”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Cited by
Items 801–900 of 1,000
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology
DeWitt, J. T., Raghunathan, M., & Haricharan, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.10.001 · Cited by 11
EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
Liu, R., Li, Z., Chen, R., Fang, Z., Liu, Z., & Liu, H. (2025) · Nature Communications · doi:10.1038/s41467-025-56506-5 · Cited by 11
Self-citationThe power and the promise of epigenetic drugs in oncology
Scandolara, T. B., Siqueira, I. V. M., Pinto, L. F. R., & Soares‐Lima, S. C. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2025.1622115 · Cited by 11
Xu, Y., Shen, H., Shang, D., & Zhu, C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1665239 · Cited by 10
AARS1-mediated lactylation of STAT1 drives immune evasion
Du, Y., He, M., Xu, Y., Tian, T., Zhou, Y., Zhang, Y., Fu, H., Li, J., Lv, L., & Xu, Y. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117094 · Cited by 12
Adaptive resistance in cancer immunotherapy
Yang, K. E., Yang, C., Xiong, K., Hao, J., & Ye, L. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01424-9 · Cited by 12
Fu, J., Xie, Y., Fu, T., Qiu, F., Yu, F., Qu, W., Yao, X., Zhang, A., Yang, Z., Shao, G., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00801-x · Cited by 10
Mi, T., Jin, L., Zhang, Z., Wang, J., Li, M., Zhanghuang, C., Tan, X., Wang, Z., Tian, X., Xiang, B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.882714 · Cited by 10
“role in the expression of chemokines (34).”
Immunomodulatory role of EV-derived non-coding RNA in lung cancer
Ghidotti, P., Petraroia, I., Fortunato, O., & Pontis, F. (2023) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2022.42 · Cited by 10
Kwantwi, L. B. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01240-9 · Cited by 10
Mendonca, P., Kaur, S., Kirpal, B., & Soliman, K. F. A. (2024) · American Journal of Cancer Research · doi:10.62347/anxs3815 · Cited by 10
“…targeting cytokines, such as CCL2, in combination with PD-1/PD-L1 inhibition may lead to an increase in T-cell infiltra - tion, antitumor immunity, and a reduction in tumor resistance to immunotherapy [75], improving the efficacy and decreasing the resis - tance against immunotherapies [76].”
Immunotherapy for castration-resistant prostate cancer: has its time arrived?
Slovin, S. F. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1735345 · Cited by 11
Regulation of chemo-sensitivity in ovarian cancer via a stroma dependent glutathione pathway
Oien, D. B., CHIEN, J. R., & Cheng, N. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.09.32 · Cited by 10
“have reported that epigenetic modulators induce tumor expression of CXCL9 and CXCL10, which enhance T cell trafficking and slow tumor progression (22).”
BackgroundChallenges and unanswered questions for the next decade of immune-oncology research in NSCLC
Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.08 · Cited by 12
Immune Checkpoint Inhibitors in AML-A New Frontier
Thummalapalli, R., Knaus, H. A., Gojo, I., & Zeidner, J. F. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666200421081455 · Cited by 11
Kosaka, A., Yajima, Y., Hatayama, M., Ikuta, K., Sasaki, T., Hirai, N., Yasuda, S., Nagata, M., Hayashi, R., Harabuchi, S., et al. (2021) · Cancer Science · doi:10.1111/cas.14973 · Cited by 12
Epigenetic mechanisms of liver tumor resistance to immunotherapy
Sanceau, J., & Gougèlet, A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.979 · Cited by 10
Epigenetics during EMT in lung cancer: EZH2 as a potential therapeutic target
Dimou, A., Dincman, T. A., Evanno, E., Gemmill, R. M., Roche, J., & Drabkin, H. A. (2017) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2017.06.003 · Cited by 11
Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities
Baretti, M., Ahuja, N., & Azad, N. S. (2019) · Annals of Pancreatic Cancer · doi:10.21037/apc.2019.10.01 · Cited by 10
Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology
Barrero, M. J. (2020) · Epigenomes · doi:10.3390/epigenomes4030022 · Cited by 10
Yang, X., Li, Y., Peng, Y., Chang, Y., He, B., Zhang, T., Zhang, S., Geng, C., Liu, Y., Li, X., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546794 · Cited by 12
Yang, M., Lei, X., Ren, D., Qin, D., & Xia, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1697428 · Cited by 11
Yang, H., Sun, Z., Zhang, Z., Song, S., Wen, H., Yang, Z., Li, X., Xiang, S., Wang, L. J., Kang, M., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c12430 · Cited by 9
Pandey, A., Rai, S. K., Ma, L., Higa, L., Khadka, V. S., Yang, H., & Deng, Y. (2026) · Advanced Science · doi:10.1002/advs.202518960 · Cited by 11
Sorrenti, E., Governa, V., Bressan, D., Cremonesi, E., Formaggio, N., Latino, I., Calì, B., Torcasio, C., Basso, C., Galafassi, J., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.02.006 · Cited by 9
Transposable Element Activation: A Hallmark of Cancer
Chiappinelli, K. B., & Burns, K. H. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-2164 · Cited by 10
Mechanism of resistance to immune checkpoint inhibitors
Pandey, M. R., & Ernstoff, M. S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.015 · Cited by 11
“Peng et al.([51]) have also shown in mouse ovarian cell line models that DNA methylation decreases the production of tumor-mediated Th1 type cytokines including CXCL9 and CXCL10, leading to decreased T cell infiltration into the tumor.”
BackgroundGonçalvès, A., Mezni, E., & Bertucci, F. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000680 · Cited by 10
“Once activated, STING initiates type I interferon (IFN) pathway, which has been shown to boost anticancer immune response [13,14], through various aspects including enhancement of antigen presentation by dendritic cells [15], increase of T-cell cytotoxicity [16] and trafficking [17], as well as inhibition of regulator…”
BackgroundShi, X., Peng, X., Chen, Y., Shi, Z., Yue, C., Zuo, L., Zhang, L., & Gao, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1326509 · Cited by 10
An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development
Wang, Q., Xie, B., Sun, J., Li, Z., Xiao, D., Tao, Y., & She, X. (2024) · Journal of Cancer · doi:10.7150/jca.92101 · Cited by 11
Unleashing precision: A review of targeted approaches in pleural mesothelioma
Occhipinti, M. A., Brambilla, M., Liello, R. D., Ambrosini, P., Lobianco, L., Leporati, R., Salvarezza, M., Vitiello, F., Marchesi, S., Manglaviti, S., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104481 · Cited by 10
Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation
Tang, Y., Zhang, R., Mao, G., Li, C., Gao, Y., Zhou, X., Nie, W., Song, T., Liu, S., Tao, K., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-024-01805-9 · Cited by 10
“Furthermore, STAT1 is the key transcription factor to regulate CXCL9 and CXCL10 expression [14].”
InfluentialBozic, T., Serša, G., Kranjc, S., Čemažar, M., & Markelc, B. (2021) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2021.107795 · Cited by 10
The current and future aspects of glioblastoma: Immunotherapy a new hope?
Patel, V., & Shah, J. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15343 · Cited by 9
Gao, C., Gu, X., Chen, Y., Zhou, M., Jiang, F., & Zheng, S. (2021) · Medical Science Monitor · doi:10.12659/msm.932275 · Cited by 9
“EZH2 is further reported to inhibit immunity by repressing the production of Th1-type chemokines CXCL9 and CXCL10 in colon and ovarian carcinomas [32,33].”
BackgroundTranscription Factors as Novel Therapeutic Targets and Drivers of Prostate Cancer Progression
Xie, K., Tan, K., & Naylor, M. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.854151 · Cited by 11
Immune mechanisms shape the clonal landscape during early progression of prostate cancer
Tshering, L. F., Luo, F., Russ, S., Szenk, M., Rubel, D., Tutuska, K., Rail, J. G., Balázsi, G., Shen, M. M., & Talos, F. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.04.010 · Cited by 10
The Role of Chromatin-Associated Proteins in Cancer
Helin, K., & Minucci, S. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034422 · Cited by 10
“Studies in ovarian cancer models have shown that EZH2-mediated histone H3K27 trimethylation and DNA methylation repress the expression of T helper chemokines (CXCL9 and CXCL10) by tumor cells, and restoration of their expression by treatment with EZH2 inhibitors increases effector T cell tumor infiltration, slows down…”
BackgroundGreten, T. F., & Korangy, F. (2017) · Gut · doi:10.1136/gutjnl-2017-315091 · Cited by 9
Augmenting engineered T-cell strategies in solid cancers through epigenetic priming
Nielsen, A., Ormhøj, M., Traynor, S., & Gjerstorff, M. F. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02661-1 · Cited by 9
The antiviral immune forces awaken in the cancer wars
Pyeon, D., Vu, L., Giacobbi, N. S., & Westrich, J. A. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008814 · Cited by 9
Chen, W., Zhang, X., Bi, K., Zhou, H., Xu, J. X., Dai, Y., & Diao, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554165 · Cited by 12
“In line with prior studies, upregulation of genes associated with immune activation and immune checkpoint proteins correlates with better prognosis, whereas upregulation of genes associated with TGF/EMT correlates with poorer prognosis (14, 49).”
ResultPyziak, K., Sroka‐Porada, A., Rzymski, T., Dulak, J., & Łoboda, A. (2021) · Drug Development Research · doi:10.1002/ddr.21796 · Cited by 10
Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer
Zhu, Y., Liu, K., & Zhu, H. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00760-w · Cited by 10
“Epigenetic dysregulation profoundly impacts both tumor and immune cell populations within the TME, enabling tumor cells to evade immune-mediated detection and clearance [230, 231].”
Epigenetic modulation to overcome immune suppression in pancreatic cancer
Drndakova, L., Juhasikova, L., Hlavenova, I., Buociková, V., Durdiakova, S., Mego, M., Buc, M., & Smolková, B. (2026) · Clinical Epigenetics · doi:10.1186/s13148-026-02081-5 · Cited by 9
Immune-epigenetic crosstalk in haematological malignancies
Wong, H., & Sugimura, R. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1233383 · Cited by 9
“…evidence shows epigenetic drugs not only extensively modi fi es the tumour epigenome in haematological malignancies, it also rewires the chromatin landscape of immune cells in the BM microenvironment, in turn modulating the extent and quality of anti-tumour immune responses (Peng et al., 2015).”
Zhuo, L., Meng, F., Sun, K., Zhou, M., & Sun, J. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02803-7 · Cited by 10
“Furthermore, epigenetic silencing of the Th1 chemokines CXCL9 and CXCL10 can alter the T cell landscape and serve as a reversible mechanism used by tumors to evade immune surveillance [41].”
Hossain, S. M., Ly, K., Sung, Y. J., Braithwaite, A. W., & Li, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810120 · Cited by 13
“DNMT and lysine methyltransferase 6A (KMT6A/EZH2) also suppress Th1-type chemokines like CXCL9 and CXCL10, crucial for T cell recruitment [64].”
BackgroundChan, W. L., Hue, S. S., Deng, L., Leong, S. M., Chng, W. J., & Ng, S. (2025) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2025.101550 · Cited by 22
Immunotherapy in Non-Small-Cell Lung Cancer: A Bridge Between Research and Clinical Practice
Passiglia, F., Commendatore, O., Vitali, M., & Conca, R. (2018) · Future Oncology · doi:10.2217/fon-2018-0098 · Cited by 10
“[137] showed that epigenetic silencing of Th1-type chemokines CXCL9 and CXCL10 inhibits T-cells homing.”
BackgroundThe Chemokine System in Oncogenic Pathways Driven by Viruses: Perspectives for Cancer Immunotherapy
Schlecht‐Louf, G., Deback, C., & Bachelerie, F. (2022) · Cancers · doi:10.3390/cancers14030848 · Cited by 9
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer
Meghani, K. A., Cooley, L. F., Piunti, A., & Meeks, J. J. (2022) · Bladder Cancer · doi:10.3233/blc-211609 · Cited by 9
Liang, Y., Liu, X., Li, K., & Li, H. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.02.07 · Cited by 9
Yang, D., Feng, Y., Lu, H., Chen, K., Xu, J., Li, P., Wang, T., Xia, D., & Wu, Y. (2023) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200292 · Cited by 8
“Tumor cells with EGFR activating mutations commonly induced immunosuppressive TME (Peng et al., 2015; Sugiyama et al., 2020; Cho et al., 2021).”
BackgroundEpigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy
Rausch, J., Ullrich, E., & Kühn, M. W. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269012 · Cited by 9
“Also, HMAtreatment is associated with tumor re-expression of endogenous retroviruses (ERVs) that is believed to improve T- and NK-cell activation via enhanced IFN-g expression (141–144), enhances tumor lymphocyte infiltration (145), and impairs expansion of regulatory T-cells (146), (Figure 1).”
BackgroundHu, Y., Zhang, X., Li, Q., Zhou, Q., Fang, D., & Lu, Y.-Y. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.09.030 · Cited by 8
“EZH2 promotes anticancer immune responses by regulating Th1 chemokine expression, myeloid-derived suppressor cells, or CD8 T cell infiltration [40,41].”
BackgroundMechanisms and measures to modulate T cell trafficking for amplified and tolerogenic immunity
Lu, Y., Liu, X., & You, J. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102129 · Cited by 9
RAB42 is a Potential Biomarker that Correlates With Immune Infiltration in Hepatocellular Carcinoma
Peng, H., Du, X., & Zhang, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.898567 · Cited by 9
“Recent studies have shown that DNA methylation modification can promote the production of immunerelated cytokines to promote tumor progression (Peng et al., 2015).”
BackgroundAdvances in Research on the Effects and Mechanisms of Chemokines and Their Receptors in Cancer
Xu, J., Li, J., Chen, Q., Shestakova, E. A., Misyurin, V. A., Pokrovsky, V. S., Tchevkina, E. M., Chen, H., Song, H., & Zhang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.920779 · Cited by 9
Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate CancerPreprint
Sheahan, A. V., Morel, K. L., Burkhart, D. L., Baca, S. C., Labbé, D. P., Roehle, K., Heckler, M., Calagua, C., Ye, H., Galbo, P. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/730135 · Cited by 8
“EZH2 can negatively regulate interferon (IFN) response genes, Th-1 type chemokines, and MHC expression in multiple tumor cell types (5, 6).”
BackgroundWang, Q., Li, S., Wu, Y., Yu, X., Dai, Y., Wang, Y., Li, L., Yang, M., Lin, K., Shao, W., et al. (2025) · Research · doi:10.34133/research.0915 · Cited by 9
“Previous studies have shown that compounds induced by T helper 1 (Th1) chemokines can convert immunologically non-inflamed tumors into inflamed tumors, thereby enhancing the therapeutic response against cancer cells [ 41 – 43 ].”
Prevention of cancer initiation by augmenting MHC-I antigen presentation via EZH2 inhibition
Ding, W., Ding, Z., Zeng, Q., Qiu, Y., Donnelly, C. R., Wu, Y., Jiang, Y., Han, Q., Xu, H. Y., Hao, C., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03646-z · Cited by 8
“The versatile and crucial functions of EZH2 in tumor progression, including tumor growth, metastasis, and stemness maintenance, most importantly, tumor immunity regulation [28 – 30], have been extensively studied, for example, in HNSCC, breast cancer, and gastric cancer.”
Persistent IFN-γ signaling in acquired resistance to PD-(L)1 blockade in NSCLC
Karri, V., & Dalia, S. M. (2025) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2025.90 · Cited by 8
Dual immune checkpoint blockade strategies for cancer therapy
Liu, Y., Yadav, U. P., Chen, C., & Wang, P. (2026) · Cell investigation. · doi:10.1016/j.clnves.2026.100064 · Cited by 7
Zhao, Y., Wang, X., Lei, T. B., Lu, H., Zhao, Y., & Wang, G. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004009 · Cited by 9
“[28] Beyond these regulatory layers, tumors may impair chemokine-mediated immune surveillance via genomic deletions — such as CXCL13 loss in colorectal cancer (CRC) [29] or through oncogene-driven repression, exemplified by the MYC -FMRP- CCL7 axis.”
Challenges & Perspectives of Immunotherapy Biomarkers & The HistoOncoImmune™ Methodology
Ung, C., & Kockx, M. M. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1140005 · Cited by 7
“cells, were less responsive, highlighting the potential role of cytotoxic T-cell biomarkers such as CD8 [32].”
BackgroundInfluentialMechanisms of primary resistance to immune checkpoint inhibitors in NSCLC
Gomatou, G., Charpidou, A. G., Li, P., Syrigos, N. K., & Gkiozos, I. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03731-x · Cited by 10
“Moreover, epigenetic modulators, for example, histone H3 lysine 27 trimethylation (H3K27me3) mediated by zeste homologue 2 (EZH2) and DNA methylation mediated by DNA methyltransferase 1 (DNMT1) suppressed expression of CXCL9 and CXCL10 to inhibit trafficking [78].”
Pharmacological Advancements of PRC2 in Cancer Therapy: A Narrative Review
Wang, M. S., Sussman, J., Xu, J.-J., Patel, R. T., Elghawy, O., & Rawla, P. (2024) · Life · doi:10.3390/life14121645 · Cited by 9
Yi, J., Quji, S., Guo, L., Chai, Z., Kong, X., & Meng, J. (2025) · Cellular Immunology · doi:10.1016/j.cellimm.2025.105026 · Cited by 8
Wang, B., Liu, M., Ran, Z., Li, X., Li, J., & Ou, Y. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00348 · Cited by 7
“, 2018; Galon and Bruni, 2019) was a critical factor responsible for these limitations (Ji et al., 2012; Peng et al., 2015; Spranger et al., 2015; Chen et al., 2016; Kortlever et al., 2017).”
BackgroundBenefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
Khatib, M. O. A., Pinton, G., Moro, L., & Porta, C. (2023) · Cancers · doi:10.3390/cancers15051537 · Cited by 8
Jia, W., Li, N., Wang, J., Gong, X., Ouédraogo, S. Y., Wang, Y., Zhao, J., Grech, G., Chen, L., & Zhan, X. (2024) · The EPMA Journal · doi:10.1007/s13167-024-00359-3 · Cited by 10
Wang, J., Lou, Y., Wang, S., Zhang, Z., You, J., Zhu, Y., Yao, Y., Hao, Y., Liu, P., & Xu, L. X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1345046 · Cited by 9
Wang, C., & Wang, L. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003152 · Cited by 7
“[94,95] The overexpression of EZH2 has already been proven in NKTCL, and DNMT1 can be upregulated by LMP-1 and LMP-2A encoded by EBV.”
BackgroundKakimi, K., & Sugie, T. (2025) · Breast Cancer · doi:10.1007/s12282-025-01707-5 · Cited by 8
“By repressing immune-related genes such as CXCL9/CXCL10 , MHC class I molecules, and interferon-stimulated genes , EZH2 contributes to immune evasion through reduced T cell recruitment and impaired antigen presentation [71].”
Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy
Cho, Y., Milane, L. S., & Amiji, M. M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1602605 · Cited by 7
“For OC, the PD-L1 blockade, when used together with a SAMdependent enzyme inhibitor and a DMNT inhibitor, DZNep and 5-aza-2′deoxycytidine, respectively, had significantly improved therapeutic efficacy compared to PD-L1 inhibition alone [82].”
New molecular tumor markers for endometrial cancer.
Numa, F., Umayahara, K., Suehiro, Y., Suminami, Y., Oga, A., Sasaki, K., & Kato, H. (2001) · PubMed · Cited by 8
Jia, H., Guo, J., Liu, Z., Chen, P., Li, Y., Li, R., Yang, Y., Li, X., Wei, P., Zhong, J., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108572 · Cited by 9
TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
Qiu, T., Wang, X., Du, F., Hu, X., Sun, F., Song, C., & Zhao, J. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02581-7 · Cited by 7
“4b), chemokines (CCL3, CXCL10, CXCL16, CXCL9, and CCL5; Fig.”
BackgroundRepurposing Food and Drug Administration–Approved Drugs to Promote Antitumor Immunity
Sukhatme, V. V., Ramalingam, S. S., Ahmed, R., & Sukhatme, V. P. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000368 · Cited by 7
Divergent fates of antigen-specific CD8+ T cell clones in mice with acute leukemia
Chen, X., MacNabb, B. W., Flood, B. A., Blazar, B. R., & Kline, J. P. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109991 · Cited by 7
“Reinvigorating the function of exhausted, leukemia-specific CD8+ T cells may be possible through epigenetic reprogramming (Peng et al., 2015), although this is speculative and will require further experimentation.”
BackgroundThe roles of cell cycle proteins in regulating the tumor immune microenvironment
Zhu, Q., Wei, X., Qu, Z., Lu, L., Zhang, Y., & Wang, H. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101706 · Cited by 9
“98,99 Furthermore, CDK4/6 inhibitors enhance the efficacy of immune checkpoint blockade therapy.”
Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events
Haugh, A. M., & DAUD, A. I. (2024) · Journal of Clinical Investigation · doi:10.1172/jci184310 · Cited by 6
“The Th1 pathway, driven by the cytokines IL-12 and IFN-γ, is thought to play a key role in response to intracellular pathogens and is thus implicated in antiviral immunity and in adaptive immune rejection of tumors (5, 6).”
BackgroundCell-type-specific subtyping of epigenomes improves prognostic stratification of cancer
Luo, Q., & Teschendorff, A. E. (2025) · Genome Medicine · doi:10.1186/s13073-025-01453-5 · Cited by 8
“…the immune-system component, and given the growing importance of epigenetically associated immune modulation in the tumor microenvironment [16, 102–104], we calculated cytokine-activity scores for cytokine signatures from the “Immune Dictionary” [82], a large compendium of 938 immune…”
Segura‐Collar, B., Cómitre-Mariano, B., López, D. A., Modejar-Ruescas, L., Caamaño-Moreno, M., Ambel, E. T., Gutierrez-Martin, J., Garin, M. I., Toldos, O., Hernández‐Laín, A., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0807 · Cited by 8
Role of Lymphocytes in Cancer Immunity and Immune Evasion Mechanisms
Kushekhar, K., Chellappa, S., Aandahl, E. M., & Taskén, K. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_10 · Cited by 7
The Heightened Importance of EZH2 in Cancer Immunotherapy
Lin, X., Zhou, W., Lin, C., & Cao, W. (2023) · Cancer Screening and Prevention · doi:10.14218/csp.2023.00006 · Cited by 7
Liao, L., Zhang, M., Xu, X., Zhang, S., & Guo, Y.-Z. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902069 · Cited by 6
Anti-Tumor Potential of Post-Translational Modifications of PD-1
Xi, X., & Zhao, W. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030136 · Cited by 7
“In cancer, epigenetic modifications silence chemokines such as CXCL9 and CXCL10 in the TME, enabling tumor immune evasion [104].”
BackgroundEZH2 Expression in Head-and-Neck Squamous Cell Cancer in Young Patients
Révész, M., Oberna, F., Slezák, A., Tóth, E., Ferenczi, Ö., Kenessey, I., & Takácsi‐Nagy, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105250 · Cited by 7
Yadigaroglu, K., Scharf, S., Gretser, S., Schäfer, H., Deli, A. S. S., Loth, A. G., Yegoryan, H., Schmitz, R., Donnadieu, E., Hansmann, M., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284512 · Cited by 7
“…to be on average 3.57/Mb in cHL nodular sclerosing type, 23 as well as differences in chemokine secretion in the neoplastic HRS cells of cHL. 24-26 These findings may explain the divergent observation of cell-cell interaction after nivolumab treatment in our study and also the large…”
BackgroundInfluentialKaczorowska, A., Miękus, N., Owczarzak, A., Gabrych, A., Wojciechowska, M., Irga‐Jaworska, N., Małgorzewicz, S., Rąpała, M., & Stefanowicz, J. (2025) · Cells · doi:10.3390/cells14040297 · Cited by 6
“Poor tumor infiltration by T cells has been attributed to potent epigenetic silencing of the genes encoding the Th1-type chemokines CXCL-9 and CXCL-10 in tumors [38,39].”
Zheng, Z., Wang, W., Feng, M., Chen, X., Ren, F., & Hou, Y. (2025) · British Journal of Haematology · doi:10.1111/bjh.20066 · Cited by 8
“23,24 However, the mechanism of EZH2/H3K27me3 in the transformation of MDS to AML has been inadequately reported at present.”
Self-citationVaccines as Priming Tools for T Cell Therapy for Epithelial Cancers
Kandalaft, L. E., & Harari, A. (2021) · Cancers · doi:10.3390/cancers13225819 · Cited by 7
“Endogenous retroviruses [41], silenced Th1 type chemokines, and components of the antigen processing and presenting machinery have also been shown to increase their expression following epigenetic treatment and thus leading to immune response activation [42].”
BackgroundResistance to Immunotherapy: Mechanisms and Means for Overcoming
Salkeni, M. A., Shin, J. Y., & Gulley, J. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_2 · Cited by 6
Raychaudhuri, R., & Ujjani, C. S. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s267011 · Cited by 6
“In animal models of ovarian and colorectal cancer, epigenetic modulation of EZH2 activity increased effector T cell tumor infiltration and improved the efficacy of PD-L1 and CTLA-4 blockade.(28,29)”
BackgroundSMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers
Ji, W., Niu, X., Yu, Y., Li, Z., Gu, L., & Lu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.955800 · Cited by 7
“Additionally, chemokines such as CXCL9 and CXCL10 can help recruit CD8 T cells to enhance immune infiltration and antitumor immunity (52).”
BackgroundZhu, X., Yang, H., Lang, J., & Zhang, Y. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2019.06.015 · Cited by 6
Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics
Knorr, D. A., Goldberg, A. D., Stein, E. M., & Tallman, M. S. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1639167 · Cited by 6
Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers
Wan, Z., Jiang, H., Li, L., Zhu, S., Hou, J., & Yu, Y. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115379 · Cited by 7
Metadata
- Authors
- Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., & Zou, W.
- Affiliations
- University of Michigan (US)
- Medical University of Lublin (PL)
- Henry Ford Health (US)
- Corresponding author
- Zou, Weiping
- ORCID
- Venue
- Nature
- Published
- 2015-10-26
- Volume
- 527
- Issue
- 7577
- Pages
- 249-253
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4779053
- OpenAlex
- W2103021272
- Cited by
- 1,201
- References
- 37
- Citations by year
- 2026: 79 · 2025: 100 · 2024: 104 · 2023: 132 · 2022: 155 · 2021: 159 · 2020: 125 · 2019: 109 · 2018: 85 · 2017: 89 · 2016: 61 · 2015: 2
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (CA099985, R01CA123088, R01CA152470, CA193136, R01CA156685, CA123088, 5P30 CA 46592, CA156685, CA152470, R01CA171306, R01CA193136, CA171306, R01CA099985, F31CA189440, R01CA190176, CA190176, P30CA046592)
- National Institute of General Medical Sciences (R01GM082856)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- epigenetic silencing, EZH2, DNMT1, CXCL9, CXCL10, ovarian cancer, tumor immunosuppression, adoptive T cell therapy, CD8+ T cells, H3K27me3, DNA methylation, histone modifications, tumor microenvironment, immunotherapy response
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, DNA (Cytosine-5-)-Methyltransferase 1, Animals, DNA (Cytosine-5-)-Methyltransferases, Female, Histones, Humans, Immunotherapy, Lysine, Ovarian Neoplasms, Prognosis, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Th1 Cells, Chemokines, Tumor Escape, DNA Methylation, Gene Silencing, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, Chemokine CXCL10, Chemokine CXCL9, B7-H1 Antigen, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.